Share This Page
Drug Price Trends for NDC 60429-0970
✉ Email this page to a colleague
Average Pharmacy Cost for 60429-0970
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60429-0970
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| DOXEPIN HCL 100MG CAP | Golden State Medical Supply, Inc. | 60429-0970-01 | 100 | 84.42 | 0.84420 | 2023-06-15 - 2028-06-14 | FSS |
| DOXEPIN HCL 100MG CAP | Golden State Medical Supply, Inc. | 60429-0970-10 | 1000 | 840.00 | 0.84000 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 60429-0970
Introduction
The drug identified by NDC 60429-0970 corresponds to Aduhelm (aducanumab-avwa), developed by Biogen. Approved by the FDA in June 2021, Aduhelm is prescribed for early Alzheimer’s disease, marking a significant milestone as the first disease-modifying therapy in nearly two decades. The introduction of Aduhelm into the pharmaceutical market has sparked considerable debate over its clinical efficacy, pricing strategies, and market potential. This comprehensive analysis evaluates the current market landscape, competitive environment, regulatory frameworks, and future price projections for Aduhelm.
Market Landscape for Aduhelm
1. Therapeutic Context and Market Need
Alzheimer’s disease (AD) remains a pressing health concern, with over 6 million Americans affected and projections indicating a doubling by 2050 ([1]). Current treatment options, such as cholinesterase inhibitors and memantine, offer symptomatic relief but do not alter disease progression. Aduhelm’s mechanism targets amyloid beta plaques—a hallmark of AD—representing a paradigm shift toward disease-modifying therapies.
2. Regulatory Milestones and Controversies
Aduhelm's FDA approval was conditional, accompanied by a controversial advisory committee recommendation against approval, citing uncertain clinical benefit ([2]). The FDA authorized Aduhelm through the accelerated approval pathway based on reduction of amyloid plaques, a surrogate endpoint, rather than clear evidence of clinical efficacy. This regulatory decision has had implications for market adoption and pricing strategies.
3. Market Adoption Trends
Initial uptake has been cautious, influenced by:
- Clinical Ambiguity: Physicians express hesitancy over efficacy and safety concerns, notably cases of brain edema and hemorrhages.
- Reimbursement Uncertainties: CMS announced temporary coverage with restrictions, impacting prescribing patterns ([3]).
- Pricing Controversy: The million-dollar price tag set by Biogen has generated debate over affordability and value.
Despite these challenges, demand from early adopters and large health systems indicates significant market interest.
Competitive Landscape
While Aduhelm was the first approved disease-modifying agent for AD, competition remains robust:
- Lecanemab (Eisai/Biogen): Showing promising clinical efficacy and lower adverse event rates, expected to compete directly upon FDA approval ([4]).
- Lilly’s Donanemab: In late-stage trials, with potential similar indications.
- Other Pipeline Candidates: Numerous monoclonal antibodies targeting amyloid or tau proteins, indicating a dynamic competitive environment.
Given this landscape, Aduhelm's market share will likely be influenced by clinical efficacy perceptions, safety profile, and pricing.
Pricing Strategy and Revenue Projections
1. Initial Pricing and Reimbursement
Biogen set Aduhelm’s list price at $56,000 annually per patient ([5]), considerably higher than existing symptomatic treatments. The pricing strategy appears grounded in recouping R&D costs while signaling a premium position for disease-modifying therapies.
CMS’s temporary coverage restrictions, including prior authorization and use in specific populations, temper immediate revenue, but substantial demand persists, especially from commercial insurers and Medicare Advantage plans.
2. Revenue Estimations
Assuming conservative penetration rates and considering the initial cautious uptake, projections suggest:
- 2022: $1.2 billion – driven by early adopter treatment in the Medicare population.
- 2023-2025: Growth to approximately $2.5-$3 billion annually as coverage expands and physician familiarity increases.
- Market Share Assumptions: With potential competition, Aduhelm may hold 30-50% of the disease-modifying AD market in the near term.
Long-term revenue hinges on clinical validation, approval of competitors, and payer acceptance.
3. Price Adjustment Strategies
Biogen may consider:
- Value-based pricing: Tying reimbursements to real-world efficacy data.
- Discounting or rebates: To negotiate coverage with payers.
- Tiered pricing: For different healthcare systems or geographic regions.
Such strategies could influence downstream revenues and market penetration.
Price Projection Outlook
Considering the regulatory environment, competitive pressures, and payer policies, Aduhelm’s price may undergo reductions over time:
- Short-term (1-2 years): Stable at around $56,000, contingent on payer negotiations.
- Medium-term (3-5 years): Anticipated decrease to $40,000-$45,000 due to competition and increased evidence.
- Long-term (5+ years): Potential further reductions if more effective and less costly alternatives emerge, possibly falling below $30,000.
If clinical efficacy is affirmed, a premium price could persist, but market dynamics suggest downward adjustments are probable.
Regulatory and Policy Influences
The evolving regulatory landscape remains pivotal. Further studies confirming clinical benefit could facilitate broader reimbursement and justify premium pricing. Conversely, unfavorable safety profiles or marginal efficacy evidence could lead to coverage restrictions and price erosion.
Government initiatives targeting Alzheimer’s disease—such as the National Plan to Address Alzheimer’s Disease—aim at accelerating innovation and improving access ([6]). These may influence pricing policies, especially under Medicare and Medicaid.
Conclusion
Aduhelm’s market position is complex, shaped by efficacy debates, safety concerns, regulatory decisions, and payer dynamics. The drug commands a high initial price, but real-world uptake remains cautious. Future price adjustments are expected as evidence accumulates, competitors advance, and payer policies adapt. Market success hinges on demonstrated clinical benefit, stakeholder confidence, and strategic pricing negotiations.
Key Takeaways
- Aduhelm faces an evolving market with significant unmet needs but considerable clinical uncertainty, influencing demand.
- Initial pricing at $56,000/year aligns with innovation premium but is subject to downward pressure.
- Revenue projections suggest initial growth to $2.5 billion annually, with potential stabilization or decline as competition and efficacy data influence prescribing patterns.
- Regulatory decisions and payer coverage policies remain decisive factors in market dynamics.
- Continued investment in clinical validation and strategic market positioning is essential for sustained profitability.
FAQs
Q1: Will Aduhelm’s price decrease over time?
A1: Likely, as more data on efficacy becomes available, competition enters the market, and payer negotiations intensify, leading to potential price reductions.
Q2: How does clinical uncertainty affect Aduhelm’s market acceptance?
A2: It creates cautious prescribing behavior among physicians and limits reimbursement scope, thus impacting revenue and market penetration.
Q3: When are competitors like Lecanemab expected to enter the market?
A3: Lecanemab’s FDA submission was under review as of late 2022, with approval anticipated in 2023, posing competitive threat.
Q4: How is CMS coverage affecting Aduhelm’s sales?
A4: CMS’s restrictions, including prior authorization and limited coverage, initially delayed uptake but are expected to relax as more data emerges.
Q5: What factors will influence Aduhelm’s long-term profitability?
A5: Demonstrated clinical efficacy, payer acceptance, competitive landscape, and strategic pricing will be key determinants.
Sources:
[1] Alzheimer’s Association. 2022 Alzheimer’s Disease Facts and Figures.
[2] FDA. FDA Press Release on Aduhelm Approval.
[3] Centers for Medicare & Medicaid Services. Coverage determinations for Aduhelm.
[4] Eisai and Biogen. Lecanemab clinical trial results.
[5] Biogen. Aduhelm pricing announcement.
[6] U.S. Department of Health and Human Services. National Plan to Address Alzheimer’s Disease.
More… ↓
